Our mission is to translate scientific advances into new treatments for people with Amyotrophic Lateral Sclerosis (ALS) and Motor Neuron Disease (MND) as rapidly as possible.
To achieve our goal, NEALS functions as an academic research consortium, a contracted research organization, and a resource tool for ALS community. Learn more about our structure.
The NEALS consortium is committed to the principles of open scientific communication, peer review, full and open disclosure of potential conflicts of interest, and democratic governance of its organization and activities.
NEALS was founded in 1995 with 9 academic clinical centers in the New England area. With help from The ALS Association’s TREAT ALS Network, Muscular Dystrophy Association, and our generous donors, the NEALS membership has grown to over 100 research centers committed to performing research in ALS and MND.
Please join Dr. Merit Cudkowicz and Dr. Sabrina Paganoni for a conversation about recent updates on AMX0035 (sodium phenylbutyrate/taurursodiol) and to review details of the Phase 3 PHOENIX Study (Study A35-004). Register here.
Please join us to learn about COURAGE-ALS, a global phase 3 trial of reldesemtiv currently enrolling participants.
Please join us on February 24th for a webinar to learn about a new Phase 2a trial of Oral LAM-002A capsules for individuals with C9ORF72 positive ALS.
The purpose of this webinar is to provide an overview of the ATLAS study, the investigational drug, eligibility criteria, and what study participation involves. This webinar will also share resources for interested individuals to learn more about study participation. This webinar will be held live on March 17, 2022. Michael Benatar, MD, PhD Professor of […]
Please join us for a conversation about Expanded Access Protocols (EAPs) in ALS, including recent progress in setting EAPs up alongside clinical trials. This webinar will be moderated by Dr. Jinsy Andrews and will feature Dr. Merit Cudkowicz, Dr. Sabrina Paganoni, Philip Green, and Sandy Morris.
A Phase 2a Study of TPN-101 in Patients with C9ORF72 ALS/FTD (Amyotrophic Lateral Sclerosis and/or Frontotemporal Dementia) Merit Cudkowicz, MD, MSc Sean M. Healey & AMG Center for ALS at Mass General Hospital Friday, May 6, 2022 10:30 - 11:30 AM EDT The purpose of this webinar is to provide an overview of a new […]
The ALS Association/Northeast ALS Consortium Educational Webinar Healey ALS Platform Trial Regimen E: A Participant's Guide Friday, June 17, 2022 5:00 - 6:00 PM EDT The purpose of this webinar is to provide an overview of how SLS-005 (trehalose) may help to slow ALS and illustrate what potential participants can expect when enrolling in Regimen […]
Matthew Harms, MD Associate Professor of Neurology at Columbia University Thursday, July 28, 2022 1:00 - 2:00 PM EDT This webinar will provide an approachable overview of the major genes involved in ALS: what those genes are, how they lead to ALS, and what ideas they are giving scientists for treating all forms of ALS. […]
Presenters: Dr. Merit Cudkowicz (Sean M. Healey & AMG Center for ALS at MGH) and Dr. Shafeeq Ladha (Barrow Neurological Institute) The purpose of this webinar is to provide an overview of how SLS-005 (trehalose) may help to slow ALS and illustrate what potential participants can expect when enrolling in Regimen E of the Healey […]
21st Annual NEALS Meeting November 1 - 3, 2022 The 2022 NEALS Meeting will be held in November in a hybrid format – both virtually and at the Opal Sands Resort in Clearwater Beach, Florida! 2022 Abstract Submission Abstract submission for the 2022 Annual NEALS Meeting is now closed. Two abstract awards will be given […]
Speakers: Dr. Merit Cudkowicz (Sean M. Healey & AMG Center for ALS at MGH) and Dr. Nazem Atassi (Sanofi) The webinar discussion will include the mechanism of action of RIPK1 inhibition, efficacy in animal models, results from Phase 1 first in human studies, and Phase 2 study design and update on enrollment.
